Skip Navigation


Rheumatology Advance Access originally published online on July 24, 2007
Rheumatology 2007 46(12):1751-1756; doi:10.1093/rheumatology/kem178
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
46/12/1751    most recent
kem178v2
kem178v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Taylor, W. J.
Right arrow Articles by Dalbeth, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, W. J.
Right arrow Articles by Dalbeth, N.
Related Collections
Right arrow Crystal Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

REVIEWS

Assessment of outcome in clinical trials of gout—a review of current measures

W. J. Taylor1, H. R. Schumacher, Jr2, J. A. Singh3,4, R. Grainger5 and N. Dalbeth6

1Rehabilitation Teaching and Research Unit, Department of Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand, 2Division of Rheumatology, University of Pennsylvania School of Medicine and Veterans Affairs Medical Center, Philadelphia, PA, 3Rheumatology Section, Medicine Service and Center for Epidemiological and Clinical Research, Center for Chronic Disease Outcomes Research at the VA Medical Center, 4Division of Rheumatology, Department of Medicine, University of Minnesota, Minneapolis, MN, USA, 5Malaghan Institute of Medical Research, Wellington and 6Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand.

Correspondence to: Dr William J. Taylor, Department of Medicine, Wellington School of Medicine and Health Sciences, University of Otago, PO Box 7343, Wellington 6242, New Zealand. E-mail: will.taylor{at}otago.ac.nz


  Abstract

There has been renewed interest in the treatment of gout with recent reported intervention studies of new agents such as etoricoxib, febuxostat and pegylated-uricase. However, these studies have highlighted the relative paucity of validated outcome measures with which to judge efficacy. This review outlines the published information regarding which endpoints have been measured in randomized clinical trials, what should be measured, what tools or instruments are available for this and the technical properties of such instruments. It highlights recent work that validates measures of tophi, radiographic damage and patient-reported outcomes. The absence of a valid definition of gout-flare or how flare reduction defines response is problematic; this forms the basis for a current ACR-EULAR sponsored project.

Submitted 5 April 2007; Accepted 25 May 2007


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.